Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Pablo M. Bedano"'
1
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemotherapy in Refractory Germ Cell Tumors
Autor: Stephen D. Williams, Lawrence H. Einhorn, Beth E. Juliar, Mary J. Brames, Pablo M. Bedano
Publikováno v: Journal of Clinical Oncology. 24:5403-5407
Purpose Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8efc25f12ff79c70d5444d8414db33ce
https://doi.org/10.1200/jco.2006.05.8065
Zobrazit plný text záznamu
2
Salvage Therapy in Patients with Advanced Non-small Cell Lung Cancer
Autor: Nasser H. Hanna, Pablo M. Bedano
Publikováno v: Journal of Thoracic Oncology. 1:582-587
Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::900e1308ac03beebf3d4a3b5137a9f7b
https://doi.org/10.1097/01243894-200607000-00015
Zobrazit plný text záznamu
3
Next generation sequencing in community oncology practice: Beneficial or economical burden?
Autor: Pablo M. Bedano, Radhika Walling, Shiroo Parshad, Arya Bolla, Janvi Bhatia, Anuj Krishna Agarwala, Gregory William Smith, Sumeet Bhatia, Mary Louise Mayer, Priti Poojary, Bilal Karim Siddiqui, Natraj Reddy Ammakkanavar
Publikováno v: Journal of Clinical Oncology. 35:102-102
102 Background: Precision genomics medicine is a fast growing in cancer care. Targeted therapy has yielded substantial benefit when appropriately used. With next generation sequencing (NSG) use increasing in non-academic setting outside clinical tria
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::66e1eb34e1f1e19bacc27e379970d393
https://doi.org/10.1200/jco.2017.35.15_suppl.102
Zobrazit plný text záznamu
4
Salvage therapy in patients with advanced non-small cell lung cancer
Autor: Pablo M, Bedano, Nasser H, Hanna
Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(6)
Patients with advanced non-small cell lung cancer continue to have a poor prognosis; most die from the disease within 1 year. Chemotherapy is beneficial for some patients in the first-line metastatic setting. Three agents, namely docetaxel, pemetrexe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::651bafeaa6ee6720fb433fb415e6d8dd
https://pubmed.ncbi.nlm.nih.gov/17409922
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje